Skip to content
Triangle logo TriangleGet started
← All settings

DISEASE & TREATMENT SETTING

Mucinous Adenocarcinoma

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

Mucinous Adenocarcinoma

Source population
Not part of this definition
Disease extent
Not part of this definition
Treatment line
Not part of this definition
Stage
Not part of this definition
Resectability
Not part of this definition
Biomarkers, prior therapy and derivation
molecular
    prior therapy
      derivation status
      source-attested
      derivation note
      Added because the terminology and the registry both attest it: an NCIt neoplasm concept named by 1 acquired study condition(s). It is absent from the NCI treatment-topic directory, which is not an exhaustive cancer inventory.
      source wording
      Source null

      Study evidence for this setting

      6 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

      NCT00262847 · Source cited / selected · Scope: narrower

      Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

      4 outcome links · 3 safety-group records · 1 quality-of-life measures

      →

      NCT00565851 · Source cited / selected · Scope: narrower

      Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fall

      6 outcome links · 8 safety-group records · 4 quality-of-life measures

      →

      NCT01081262 · Registry condition search · Scope: narrower

      Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stag

      6 outcome links · 4 safety-group records · 2 quality-of-life measures

      →

      NCT01167712 · Source cited / selected · Scope: narrower

      Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian

      4 outcome links · 2 safety-group records · 1 quality-of-life measures

      →

      NCT02040142 · Registry condition search · Scope: narrower

      HIPEC for Peritoneal Carcinomatosis

      4 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT02142803 · Registry condition search · Scope: narrower

      TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors

      6 outcome links · 3 safety-group records · 1 quality-of-life measures

      →
      Source relationships and population-mapping limitations
      bindings
      1. release id
        clinical-indications-draft-1
        disease state id
        ds-mucinous-adenocarcinoma
        binding id
        ncit-C26712
        source collection
        ncit-concept
        source key
        C26712
        source excerpt
        Source null
        match status
        exact
        match note
        Source null
        recorded at
        2026-09-10T00:00:00Z
      mappings

        Download this complete draft source relationship record →

        Preserved source evidence · Not medical advice